Latest News

ZEUS Trial: IL-6 Inhibition in ASCVD and CKD
Written by: Radcliffe CKM
ZEUS Trial: IL-6 Inhibition in ASCVD and CKD
Olezarsen Cuts Triglycerides and Pancreatitis Risk
Written by: Radcliffe CKM
Olezarsen Cuts Triglycerides and Pancreatitis Risk
AI Screening Improves ATTR-CM Diagnosis Rates
Written by: Radcliffe Cardiology
AI Screening Improves ATTR-CM Diagnosis Rates
Olpasiran's ApoB Reduction Explained by Lp(a) Clearance
Written by: Radcliffe Cardiology
Olpasiran's ApoB Reduction Explained by Lp(a) Clearance
Albuminuria Change Validated as CKD Surrogate Endpoint
Written by: Radcliffe CKM
Albuminuria Change Validated as CKD Surrogate Endpoint
Balcinrenone Plus Dapagliflozin Cuts Albuminuria in CKD
Written by: Radcliffe CKM
Balcinrenone Plus Dapagliflozin Cuts Albuminuria in CKD
Semaglutide Improves PAD Outcomes Regardless of Sex
Written by: Radcliffe CKM
Semaglutide Improves PAD Outcomes Regardless of Sex
Tirzepatide and Semaglutide: Comparable CV Outcomes
Written by: Radcliffe CKM
Tirzepatide and Semaglutide: Comparable CV Outcomes
Pemvidutide for MASH: IMPACT Trial 24-Week Results
Written by: Radcliffe CKM
Pemvidutide for MASH: IMPACT Trial 24-Week Results
Fish Oil Cuts CV Events in Haemodialysis Patients
Written by: Radcliffe CKM
Fish Oil Cuts CV Events in Haemodialysis Patients

External news

Written by: Cardiovascular Business
Topaz vs. Evoque: New head-to-head study for TTVR devices now underway
Written by: Cardiovascular Business
New heart drug from AstraZeneca and Ionis falls short in clinical trial
Written by: Medscape
HRT Reduces Mortality in Women With Bilateral Oophorectomy
Written by: Medscape
Pulmonary Arterial Hypertension
Written by: Cardiac Vascular News
Retia Medical Appoints Christopher Benassi to Strategic Advisory Board
Written by: Cardiac Vascular News
Stereotaxis Completes Acquisition of Robocath
Written by: Cardiac Vascular News
VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial
Written by: Cardiac Vascular News
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
Written by: Cardiac Vascular News
AccurKardia and Wellysis Sign Multi-Year Agreement to Provide Wellysis’ Turnkey Cardiac Monitoring Offering in the U.S. Market
Written by: Cardiac Vascular News
Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk